help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jian, B.
Right arrow Articles by Levy, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jian, B.
Right arrow Articles by Levy, R. J.
(American Journal of Pathology. 2002;161:2111-2121.)
© 2002 American Society for Investigative Pathology


Regular Articles

Serotonin Mechanisms in Heart Valve Disease I

Serotonin-Induced Up-Regulation of Transforming Growth Factor-ß1 via G-Protein Signal Transduction in Aortic Valve Interstitial Cells

Bo Jian*, Jie Xu*, Jeanne Connolly*, Rashmin C. Savani{dagger}, Navneet Narula{ddagger}, Bruce Liang§ and Robert J. Levy*

From the Cardiology Research Laboratory* and the Division of Neonatology,{dagger} Children’s Hospital of Philadelphia, Philadelphia; and the Departments of Pediatrics, Pathology,{ddagger} and Medicine,§ University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Clinical disorders associated with increased serotonin [5-hydroxytryptamine (5-HT)] levels, such as carcinoid syndrome, and the use of serotonin agonists, such as fenfluoramine have been associated with a valvulopathy characterized by hyperplastic valvular and endocardial lesions with increased extracellular matrix. Furthermore, 5-HT has been demonstrated to up-regulate transforming growth factor (TGF)-ß in mesangial cells via G-protein signal transduction. We investigated the hypothesis that increased exposure of heart valve interstitial cells to 5-HT may result in increased TGF-ß1 expression and activity because of serotonin receptor-mediated signal transduction with activation of G{alpha}q, and subsequently up-regulation of phospholipase C. Thus, in the present study we performed a clinical-pathological investigation of retrieved carcinoid and normal valve cusps using immunohistochemical techniques to detect the presence of TGF-ß1 and other proteins associated with TGF-ß expression, including TGF-ß receptors I and II, latent TGF-ß-associated peptide (LAP), and {alpha}-smooth muscle actin. Carcinoid valve cusps demonstrated the unusual finding of widespread smooth muscle actin involving the interstitial cells in the periphery of carcinoid nodules; these same cells were also positive for LAP. Normal valve cusps were only focally positive for smooth muscle actin and LAP. In sheep aortic valve interstitial cell cultures 5-HT induced TGF-ß1 mRNA production and increased TGF-ß1 activity. 5-HT also increased collagen biosynthesis at the dosages studied. Furthermore, TGF-ß1 added to SAVIC cultures increased the production of sulfated glycan and hyaluronic acid. In addition, overexpression of G{alpha}q using an adenoviral expression vector for a constitutively active G{alpha}q mutant (Q209L-G{alpha}q) resulted in increased phospholipase C activity as well as up-regulation of TGF-ß expression and activity. These results strongly support the view that G-protein-related signal transduction is involved in 5-HT up-regulation of TGF-ß1. In conclusion, 5-HT-associated valve disease may be, in part, because of TGF-ß1 mechanisms.





This article has been cited by other articles:


Home page
Eur Respir JHome page
A. Fabre, J. Marchal-Somme, S. Marchand-Adam, C. Quesnel, R. Borie, M. Dehoux, C. Ruffie, J. Callebert, J-M. Launay, D. Henin, et al.
Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice
Eur. Respir. J., August 1, 2008; 32(2): 426 - 436.
[Abstract] [Full Text] [PDF]


Home page
Eur J EchocardiogrHome page
V. G. Rasmussen, S. H. Poulsen, E. Dupont, K. Ostergaard, G. Safikhany, and H. Egeblad
Ergotamine-derived dopamine agonists and left ventricular function in Parkinson patients: systolic and diastolic function studied by conventional echocardiography, tissue Doppler imaging, and two-dimensional speckle tracking
Eur J Echocardiogr, May 7, 2008; (2008) jen160v1.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
P. Snider, R. B. Hinton, R. A. Moreno-Rodriguez, J. Wang, R. Rogers, A. Lindsley, F. Li, D. A. Ingram, D. Menick, L. Field, et al.
Periostin Is Required for Maturation and Extracellular Matrix Stabilization of Noncardiomyocyte Lineages of the Heart
Circ. Res., April 11, 2008; 102(7): 752 - 760.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
K. B. Donnelly
Cardiac Valvular Pathology: Comparative Pathology and Animal Models of Acquired Cardiac Valvular Diseases
Toxicol Pathol, February 1, 2008; 36(2): 204 - 217.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Bhattacharyya, J. Davar, G. Dreyfus, and M. E. Caplin
Carcinoid Heart Disease
Circulation, December 11, 2007; 116(24): 2860 - 2865.
[Full Text] [PDF]


Home page
Am. J. Pathol.Home page
A. C. Liu, V. R. Joag, and A. I. Gotlieb
The Emerging Role of Valve Interstitial Cell Phenotypes in Regulating Heart Valve Pathobiology
Am. J. Pathol., November 1, 2007; 171(5): 1407 - 1418.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K.J. Grande-Allen, N. Osman, M.L. Ballinger, H. Dadlani, S. Marasco, and P.J. Little
Glycosaminoglycan synthesis and structure as targets for the prevention of calcific aortic valve disease
Cardiovasc Res, October 1, 2007; 76(1): 19 - 28.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S. Droogmans, P. R. Franken, C. Garbar, C. Weytjens, B. Cosyns, T. Lahoutte, V. Caveliers, M. Pipeleers-Marichal, A. Bossuyt, D. Schoors, et al.
In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology
Eur. Heart J., September 1, 2007; 28(17): 2156 - 2162.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. N. Clark-Greuel, J. M. Connolly, E. Sorichillo, N. R. Narula, H. S. Rapoport, E. R. Mohler III, J. H. Gorman III, R. C. Gorman, and R. J. Levy
Transforming Growth Factor-{beta}1 Mechanisms in Aortic Valve Calcification: Increased Alkaline Phosphatase and Related Events
Ann. Thorac. Surg., March 1, 2007; 83(3): 946 - 953.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
R. G. Ruddell, F. Oakley, Z. Hussain, I. Yeung, L. J. Bryan-Lluka, G. A. Ramm, and D. A. Mann
A Role for Serotonin (5-HT) in Hepatic Stellate Cell Function and Liver Fibrosis
Am. J. Pathol., September 1, 2006; 169(3): 861 - 876.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. Zolkowska, R. B. Rothman, and M. H. Baumann
Amphetamine Analogs Increase Plasma Serotonin: Implications for Cardiac and Pulmonary Disease
J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 604 - 610.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. J. Levy
Serotonin Transporter Mechanisms and Cardiac Disease
Circulation, January 3, 2006; 113(1): 2 - 4.
[Full Text] [PDF]


Home page
CirculationHome page
A. Mekontso-Dessap, F. Brouri, O. Pascal, P. Lechat, N. Hanoun, L. Lanfumey, I. Seif, N. Benhaiem-Sigaux, M. Kirsch, M. Hamon, et al.
Deficiency of the 5-Hydroxytryptamine Transporter Gene Leads to Cardiac Fibrosis and Valvulopathy in Mice
Circulation, January 3, 2006; 113(1): 81 - 89.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
C. S. Elangbam, R. M. Lightfoot, L. W. Yoon, D. R. Creech, R. S. Geske, C. W. Crumbley, L. D. Gates, and H. G. Wall
5-Hydroxytryptamine (5HT) Receptors in the Heart Valves of Cynomolgus Monkeys and Sprague-Dawley Rats
J. Histochem. Cytochem., May 1, 2005; 53(5): 671 - 677.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
G. A. Walker, K. S. Masters, D. N. Shah, K. S. Anseth, and L. A. Leinwand
Valvular Myofibroblast Activation by Transforming Growth Factor-{beta}: Implications for Pathological Extracellular Matrix Remodeling in Heart Valve Disease
Circ. Res., August 6, 2004; 95(3): 253 - 260.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Society for Investigative Pathology.